ArticleCancer cell international2026
Divergent effects of topical deferoxamine treatment on skin and cancer cells uncovers its potential as a safe radioprotective agent in oncological applications.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDeferoxamine Intradermal Delivery Patch (DIDP; TauTona Group) represents a novel experimental therapeutic modality with the potential to mitigate radiation-induced skin injury in breast cancer patients undergoing radiotherapy. Nonetheless, the safety profile of DIDP in oncological applications has not been extensively explored. Thus, this study aims to investigate the effect of DIDP on mammary tumor cell biology using a murine xenograft human breast cancer model.
methodsA xenograft human breast cancer model was established by engrafting human-derived MCF7-Luc2 breast cancer cells into the mammary fat pads of female NCG mice. Tumor growth was monitored weekly using the Lago X Bioluminescence Imaging System. The size and volume of excised tumors were recorded. The effect of DIDP treatment on skin and tumor tissue were evaluated using qRT-PCR, immunofluorescence staining, and TUNEL staining.
resultsOur findings demonstrate that topical deferoxamine treatment does not significantly affect tumor growth and cancer cell proliferation in a xenograft human breast cancer model, indicating its safety in oncological settings. Interestingly, mice treated with DIDP exhibited a significant increase in cancer cell apoptosis, suggesting a potential regulatory effect of DIDP on this pathway in cancer cells residing in deeper tissue.
conclusionsThese results support the use of DIDP as a safe radioprotective agent that does not enhance tumor progression. Further studies are warranted to explore the mechanistic role of DIDP in regulating cancer cell apoptosis and its broader implications for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.